The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.

Nerandomilast improved patients’ lung function to a greater degree than placebo, but safety data will be key.

Two licensing deals on the same day show that radiopharmaceuticals is still an active area.

Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.